Acknowledgments
Autosomal Dominant Polycystic Kidney Disease
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
The development of this manuscript was supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (Rockville, MD). Editorial and writing services, including writing of a first draft, were provided by Andrew J. Horgan, PhD, of BioScience Communications, Inc. (New York, NY), activities that were also funded by Otsuka. Portions of the data presented in the manuscript were presented at the 58th ERA-EDTA Congress, held virtually June 5–8, 2021, and at the 53rd ESPN Annual Meeting, held September 16–19, 2021, in Amsterdam, The Netherlands.See related editorial, “Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?,” on pages 11–13.